Immune Response News and Research

RSS

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Genetic marker linked to higher risk of death in COVID-19 patients

A new study discusses the importance of single nucleotide polymorphisms in the Rab46 gene as a marker of adverse outcomes in high-risk COVID-19 patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Echinacea as a potential force against coronavirus infections

A new review identified clinical studies evaluating coronavirus infections in the context of Echinacea administration and assessed preventive and therapy advantages against COVID-19.

21 Jan 2022

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

A new study analyzed new data on the Omicron variant and indicated the altered cell entry pathways compared to other variants.

21 Jan 2022

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years.

21 Jan 2022

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

Study uncovers clue to why pigs don't get sick when exposed to COVID-19

Iowa State University scientists may have uncovered an important clue that sheds light on why pigs don't get sick when exposed to the coronavirus

20 Jan 2022

Research shows benefits of hybrid immunity to SARS-CoV-2

Researchers examine the effects of previous SARS-CoV-2 infections on the immunity offered by SARS-CoV-2 vaccination.

20 Jan 2022

Cancer patients receiving treatment may mount inadequate immune response to COVID-19 vaccination

A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy - and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells - may mount an inadequate immune response to COVID-19 vaccination.

20 Jan 2022

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

A new analysis parses out what scientists currently know about the Delta variant and predicts what the end of the COVID-19 pandemic might look like.

20 Jan 2022

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

In a new study, scientists focused on the SARS-CoV-2 Beta variant and used computational methods to design and develop effective glycoprotein multi-epitope subunit vaccine candidates, based on the old and the new Beta virus strains.

20 Jan 2022

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

A new study aimed to understand the risk of COVID-19 infection given certain serological parameters, in a group of vaccinated healthcare workers with high rates of exposure to the virus, followed up at 9 months from vaccination.

20 Jan 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

Investigational cancer drug mimics the metabolic and therapeutic effects of fasting, mice study shows

An investigational cancer drug that starves tumors of their energy supply also shows evidence of improving whole body metabolism, according to a new study in mice from Washington University School of Medicine in St. Louis.

19 Jan 2022

‘Decoy’ protein mitigates lung damage, death induced by aggressive SARS-CoV-2 variants

A drug treatment that acts as a decoy against SARS-CoV-2 was highly effective at preventing death and lung damage in humanized animal models of severe COVID-19 disease, according to a Nature Chemical Biology study from researchers at the University of Illinois Chicago.

19 Jan 2022

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

A new study aimed to highlight the different smart and emerging nanomaterials used to detect SARS-CoV-2.

19 Jan 2022

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Researchers have discovered a new way to induce immunity against the RBD.

19 Jan 2022

Immune Response News and Research

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Genetic marker linked to higher risk of death in COVID-19 patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Echinacea as a potential force against coronavirus infections

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

New COVID-19 vaccine promises vaccine equity because it has no patents

Patient, beware: Some states still pushing ineffective covid antibody treatments

Study uncovers clue to why pigs don't get sick when exposed to COVID-19

Research shows benefits of hybrid immunity to SARS-CoV-2

Cancer patients receiving treatment may mount inadequate immune response to COVID-19 vaccination

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

Investigational cancer drug mimics the metabolic and therapeutic effects of fasting, mice study shows

‘Decoy’ protein mitigates lung damage, death induced by aggressive SARS-CoV-2 variants

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News